✨ Medicines Consent Notices
19 APRIL
NEW ZEALAND GAZETTE
915
Product:
Infanrix-penta
Active Ingredient(s):
Adsorbed tetanus vaccine 40IU/dose
Diphtheria toxoid (adsorbed) 30IU/dose
Hepatitis B surface antigen (recombinant) 10µg/dose
Pertussis 69kDa outer membrane protein (Pertactin) 8µg/dose
Pertussis filamentous haemagglutinin 25µg/dose
Pertussis toxoid (adsorbed) 25µg/dose
Polio virus type 1 40DAgU
Polio virus type 2 8DAgU
Polio virus type 3 32DAgU
Dosage Form:
Suspension for injection
New Zealand Sponsor:
SmithKline Beecham (NZ) Limited
Manufacturer(s):
SmithKline Beecham Biologicals SA, Rixensart, Belgium
Product:
Miacalcic 200 IU Nasal Spray
Active Ingredient(s):
Salcatonin 200IU/dose
Dosage Form:
Solution for inhalation
New Zealand Sponsor:
Novartis New Zealand Ltd
Manufacturer(s):
MIPHARM S.p.A, Milano, Italy
Novartis Pharma AG, Basel, Switzerland
Novartis Pharma SA, Huningue, France
Dated this 11th day of April 2001.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go2750
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product:
Clozaril
Active Ingredient(s):
Clozapine 100mg
Dosage Form:
Tablet
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer(s):
Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United Kingdom
This consent is given subject to the following conditions:
- Clozapine may only be prescribed by:
(a) medical practitioners who are vocationally registered under the Medical Practitioners Act 1995 in the branches of psychological medicine or psychiatry; and
(b) medical practitioners employed as Registrars in psychological medicine or psychiatry who are under the supervision of persons of the kind referred to above. - Persons prescribing Clozapine must comply with the requirements of the New Zealand Guidelines for the use of Atypical Anti-Psychotic Drugs (2nd Edition, September 1998) and the requirements of local Hospital and Health Service Protocols for use of Clozapine.
Note: This consent is valid for 2 years from 4 February 2001.
Product:
Clozaril
Active Ingredient(s):
Clozapine 25mg
Dosage Form:
Tablet
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer(s):
Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United Kingdom
This consent is given subject to the following conditions:
- Clozapine may only be prescribed by:
(a) medical practitioners who are vocationally registered under the Medical Practitioners Act 1995 in the branches of psychological medicine or psychiatry; and
(b) medical practitioners employed as Registrars in psychological medicine or psychiatry who are under the supervision of persons of the kind referred to above. - Persons prescribing Clozapine must comply with the requirements of the New Zealand Guidelines for the use of Atypical Anti-Psychotic Drugs (2nd Edition, September 1998) and the requirements of local Hospital and Health Service Protocols for use of Clozapine.
Note: This consent is valid for 2 years from 4 February 2001.
Dated this 11th day of April 2001.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go2752
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2001, No 41
Gazette.govt.nz —
NZ Gazette 2001, No 41
✨ LLM interpretation of page content
🏥
Consent to the Distribution of New Medicines
(continued from previous page)
🏥 Health & Social Welfare11 April 2001
Medicines, Consent, Distribution, Infanrix-penta, Miacalcic
- G. R. Boyd, Chief Advisor, Safety and Regulation
🏥 Renewal of Provisional Consent to the Distribution of a New Medicine
🏥 Health & Social Welfare11 April 2001
Medicines, Consent, Distribution, Clozaril
- G. R. Boyd, Chief Advisor, Safety and Regulation